SOMATROPIN

Brand name:

• Saizen®

Pharmaceutical company:

Merck Healthcare Pty Ltd

Condition/indication:
(therapeutic use)

• Severe late onset growth hormone deficiency (GHD)

PBAC Submission type:

Change to listing (Category 3)

Comment:

--

Public Summary Document:

PBAC Public Summary Documents – September 2023 meeting

Related medicines:

--

Submission received for:

September 2023 PBAC meeting

Opportunity for consumer comment:

Open 29/03/2023 and close 24/05/2023 (see PBS Website)

PBAC meeting:

Held on 01/09/2023

PBAC outcome published:

Recommended (see PBAC Outcomes)

Notice of intent submitted:

Exception applied

Lodgement of required documentation:

11/09/2023

Acceptance of complete documentation:

Accepted

Agreement to listing arrangements:

Commenced on 19/09/2023

Status:

Finalised

Government processes:

Commenced on 19/09/2023

Medicine listed on the PBS:

01/11/2023 (see PBS schedule)

---